Compare Nuscale Power Corporation (SMR) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs TransMedics Group Inc — how do they compare? Nuscale Power Corporation trades at $7.2 (market cap $3.00B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Nuscale Power Corporation and TransMedics Group Inc are close in size by market cap, and TransMedics Group Inc is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuscale Power Corporation for 29 Days and TransMedics Group Inc for 24 Days on average.
| SMR | TMDX | |
|---|---|---|
Market Cap | $3.00B | $2.74B |
Volume | 43,143,109 | 949,331 |
Sector | Industrials | Health |
52-Week High | $53.43 | $150.42 |
52-Week Low | $7.32 | $61.99 |
Typical Hold Time | 29 Days | 24 Days |
Enterprise Value | $1.93B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMR trades at $7.145, down 6.84% on the day, reflecting ongoing investor concerns. The stock is technically bearish with moving averages signaling a downtrend, while fundamentals show severe losses with a net income margin of -3,888.7% in 2026 and negative cash flow from operations. Recent news highlights a Pomerantz law firm investigation into the company, adding to headwinds despite some analyst optimism.
The outlook remains high-risk; while 50% of analysts rate it a buy with a $11.25 consensus target, persistent losses, cash burn, and competitive pressures in the nuclear SMR space pose significant challenges. Upside depends on successful commercialization, but current financials and sentiment suggest caution.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
